Log in

AIDS: encouraging new data for a drug candidate to Abivax

The French biotech Abivax Tuesday unveiled new clinical Phase IIa results of its drug candidate against AIDS, confirming its therapeutic potential in having highlighted its "possible" impact on HIV reservoirs, the company said.


Fresenius Kabi acquires US Akorn for over 4 billion euros

Fresenius Kabi, German specialist for infusion products, said Tuesday the US manufacturer of the redemption Akorn drugs for over 4 billion, and that of the biosimilar activity of fellow Merck KGaA.


Job: Head formulation development (injectable) M / F

General information



Job Description

Job Title
Activity rate

Toulouse - Langlade (31)
Galenic development manager (injectable) H / F
Within the platform Industrialization of R & D PFM, in your capacity as referent in the formulation and processes for injectable products, you are supporting the development of all the injectable forms entrusted to the Pharmaceutical Engineering Department Forms and Processes (IFPP) and that assessing applications OPHRDC.
You drive industrialization projects (all laws) entrusted to you in scientific term, documentary, planning and compliance processes. You participate in the expertise and scientific advice on all matters CMC back to the platform Industrialization.

As such, you :
  • Take charge of the realization in internal and / or outsourced technical actions selected for the development of injectable formulations and processes, after assessment and recommendations, in accordance with the processes in place;
  • Establish close cooperation with the relevant industrial sites for joint technical analysis of industrialization injectables trials;
  • Bring your technical expertise to technicians in charge of managing the pilot injection tool;
  • Participate in the evaluation of requests from the OPHRDC;
  • Participate in the animation of the pharmaceutical community in order to improve the skills and services rendered, in close cooperation with the formulation development of Platform Manager New Chemical Entities (NCEs);
  • Are referent to develop approaches Quality by Design (QbD) on development projects;
  • Participate in the management process of industrialization in the project portfolio (all dosage forms) for an overview of the required / acquired / left to do from a scientific point of view documentary, planning on the part Drug Product;
  • Join the expertise and scientific and tactical recommendations on CMC issues dating back to the Industrialization Platform from the Innovation Unit / Development Teams (CHC, NEC or NEB), the CDMO, the Industrial or Compliance through appropriate scientific and methodological approach;
  • Develop a network of experts and scientific partners to address the issues in the field of injectables.


PhD in Pharmaceutical Sciences (formulation chemistry, physical chemistry) or Chemical Engineer / Pharmacist
specialized formulation.
Demonstrated experience 5 years minimum in the pharmaceutical development of injectable formulations and processesincluding industrialization of the finished products missions.
pharmaceutical engineering expertise (processes studies and transposition of scale factors) for formsinjectables.
Knowledge of international standards and guidelines (GMP, GMP, ICH ...) and expectations of authoritiesguardianship (FDA, EMA, ANSM).
Ability to transverse management and multi-project management at all stages of development.
Fluent English.

You are known for your strong scientific curiosity, your capacity for innovation, responsiveness, your mindteam and your sense of the result.

candidate criteria

Minimum level of education required


Science specialty

Minimum Experience Level


Bac + 4 / 5 Bac +

4-Master / Master / DEA / DESS / ESC / Engineer

Science - Chemistry, Science - Engineering formulation

5 years or more

English (4 - Current)

Date of taking officedesired:01 / 07 / 2017
Apply by following this link:http://www.pierre-fabre.com/fr


Servier recovers all commercial rights to a cancer outside the US

The French pharmaceutical group Servier will recover all non-US commercial rights of the anticancer drug Pixuvri under enlargement Tuesday its licensing and collaboration agreement with US biotech CTI BioPharma.


The CHU reduced their deficit by more than half in 2016

University Hospitals (CHU) have reduced their deficit by more than half in 2016 in a context "particularly constrained", "at the expense of lower investment," announced Monday the Conference of Directors General of these institutions.


a3p-100pxhaut logo


Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb here )

  group    administrators A3P
& Project Managers

letter   newsletter A3P